Study #2025-0476
CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Tolerability, And Clinical Activity Of CBX-250 In Participants With Relapsed Or Refractory Myeloid Leukemias.
MD Anderson Study Status
Enrolling
Treatment Agent
CBX-250
Description
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Study phase:
Phase I
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?